CHF and arrhythmias:

Indications for BIDIL:

Heart failure (HF) in black patients, as adjunct to standard treatment, to improve survival, prolong time to hospitalization for HF, and improve patient-reported functional status.

Limitations of Use:

Not established in NYHA Class IV HF.


Initially 1 tab 3 times daily, may reduce to ½ tab 3 times daily if not tolerated; titrate as tolerated after 3–5 days. Max 2 tabs 3 times daily.


Not established.


Allergy to organic nitrates. Concomitant PDE5 inhibitors (eg, avanafil, sildenafil, tadalafil, vardenafil), or riociguat.


Correct volume/salt depletion prior to initiation. Hypotension. Hypertrophic cardiomyopathy. Discontinue if syncope occurs. Give pyridoxine if peripheral neuritis occurs. Elderly. Pregnancy. Nursing mothers.

Pharmacologic Class:

Vasodilators (nitrate + direct-acting).


See Contraindications. Severe hypotension with PDE5 inhibitors or riociguat.

Adverse Reactions:

Headache, dizziness, asthenia, nausea, vomiting, hypotension, sinusitis, tachycardia, paresthesia, amblyopia; SLE.

How Supplied:


Pricing for BIDIL

20mg/37.5mg tablet (Qty: 90)
Appx. price $351